Tempest Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals

Brisbane, calif., april 09, 2024 (globe newswire) -- tempest therapeutics, inc. (nasdaq: tpst), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the beth israel deaconess medical center (bidmc) at havard medical presented preclinical data at the american association for cancer research (aacr) annual meeting demonstrating that tpst-1120 reduces kidney cancer (rcc) growth as a monotherapy, while also showing increased inhibition when combined with frontline chemotherapy and immunotherapy. these new data further support the clinical benefit observed in the tpst-1120 phase 1 data presented in an oral presentation at asco 2022.

Brisbane, calif., april 04, 2024 (globe newswire) -- tempest therapeutics, inc. (nasdaq: tpst), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that cancer research communications published positive clinical data from the dose-escalation phase 1 trial of tpst-1120 in an article titled “first-in-human phase i trial of tpst-1120, an inhibitor of pparΑ, as monotherapy or in combination with nivolumab, in patients with advanced solid tumors.” the data showed that tpst-1120 demonstrated clinical activity, including tumor shrinkage, even in pd-1 inhibitor refractory and immune compromised cancers, and was well tolerated both as monotherapy and in combination with nivolumab...

Brisbane, calif., march 19, 2024 (globe newswire) -- tempest therapeutics, inc. (nasdaq: tpst), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the year ended 2023 and provided a corporate update.

New york--(business wire)--glancy prongay & murray llp (“gpm”) announces its investigation of tempest therapeutics, inc. (nasdaq: tpst) concerning the company and its directors' and officers' possible violations of state laws. if you own tempest therapeutics stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact tom kennedy, of gpm, 230 park avenue, suite 358, new york,.

Brisbane, calif., march 05, 2024 (globe newswire) -- tempest therapeutics, inc. (nasdaq: tpst), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the beth israel deaconess medical center (bidmc) at havard medical school will present a poster with preclinical data supporting the advancement of tpst-1120 as a potential treatment for renal cell carcinoma (rcc) at the american association for cancer research (aacr) annual meeting taking place april 5-10, 2024 in san diego, ca.

Tempest Therapeutics, Inc. achieved positive results from phase 1b/2 study using TPST-1120 + Tecentriq + Avastin for the treatment of patients with 1st-line HCC; Significant improvements in both confirmed and unconfirmed responses. Updated results from the phase 1b/2 study, using TPST-1120 + Tecentriq + Avastin for the treatment of patients with 1st-line HCC, are expected in 2024. It is expected that the global liver cancer drug market size is expected to reach $7.6 billion by 2033.

Remarkably, the stock did not have fundamentally changing news. It did not rocket higher on breaking news that would typically be associated with the whopping gains it experienced.

Shares of Tempest Therapeutics Inc. TPST, -8.54% fell more than 8% Friday to conclude a dramatic week in which the stock clocked a one-day gain of nearly 4,000%.

Shares of microcap oncology company Tempest Therapeutics Inc. TPST, -55.06% dropped more than 50% Thursday as investors took a breath after the stock's roughly 40-fold gain on Wednesday.

Tempest (TPST) skyrockets 2879% on positive new and updated findings from its early-mid-stage study evaluating TPST-1120 in combination with standard-of-care therapies to treat liver cancer.

Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer's acquisition of Seagen, Eli Lilly's buyout of POINT Biopharma and Versanis Bio, and Roche's purchase of Good Therapeutics.

Today, most of Wall Street is watching Tempest Therapeutics (NASDAQ: TPST ). This little-known clinical-stage oncology company has gone from trading at 30 cents per share 24 hours ago to its current share price of $6.40.

Tempest Therapeutics (NASDAQ: TPST ) is the stock to watch for today, as its shares are up by a staggering 1,500%. This morning, the cancer therapies company reported positive results for its TPST-1120 drug candidate in its randomized Phase 1b/2 clinical study.

Shares of Tempest Therapeutics Inc. TPST, +1942.52% soared more than 1,900% on Wednesday after the company released study results for its investigational cancer treatment TPST-1120 in patients with liver cancer.

Tempest Therapeutics (NASDAQ: TPST ) stock is taking off on Wednesday as the clinical-stage oncology company prepares to release new study results. According to a press release from the company, it intends to release updated study results from a Phase 1b/2 combination study of TPST-1120 with atezolizumab and bevacizumab.